drugset / Trial / NCT05359341
Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?
RandomizedParallel-groupOpen-labelTreatment
Summary
Our trial goal is to determine the efficacy and safety of sitagliptin in comparison with empagliflozin in type 2 diabetic Egyptian patients.
Timeline
- Start
- 2020-09-20
- Primary completion
- 2021-09-20
- Completion
- 2022-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Empagliflozin | Small molecule | 12.5 mg | — |
| Comparator | Sitagliptin | Small molecule | 50 mg | — |